Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial Source: Eur Respir J 2006; 28: 670 Year: 2006
Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002
Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease: A nationwide population-based study Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003
Heliox and alveolar oxygenation in patients with chronic obstructive pulmonary disease: a multicentre, randomised, crossover study Source: Eur Respir J 2004; 24: Suppl. 48, 243s Year: 2004
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial Source: Eur Respir J, 50 (1) 1601448; 10.1183/13993003.01448-2016 Year: 2017
Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002
Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
The beta-blockers in combined treatment of coronary heart disease in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD treatment Year: 2013
Non-invasive positive pressure ventilation (NIPPV)for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial Source: Eur Respir J 2003; 22: Suppl. 45, 403s Year: 2003
Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009
Effects of Diltiazem on pulmonary hemodynamics and right heart function in patients with chronic obstructive pulmonary disease (COPD)> Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020
Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study. Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Maintaining benefits following pulmonary rehabilitation: a randomised controlled trial Source: Eur Respir J 2010; 35: 571-577 Year: 2010
Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012